✨ Free AI Report
Cleerly, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Cleerly, Inc.
Company Research

Cleerly, Inc.: Business Overview, Financials & Competitive Analysis

Cleerly, Inc. scores 8/10 on the AskCyborg Cyborg Score (Strong). Cleerly is positioned to capture significant market share in AI-driven coronary diagnostics with regulatory tailwinds and clinical evidence, though IP/competitive disputes may impact growth velocity. Cleerly commands a strong competitive position with FDA clearance, recent Medicare coverage, substantial funding ($388-578M raised to date), and clinical validation across 40,000+ patients. However.

What is Cleerly, Inc.'s industry? Cleerly, Inc. (cleerlyhealth.com) operates in Cardiovascular Devices. AskCyborg classifies Cleerly, Inc. under Cardiovascular Devices in its company registry.

Cleerly is a healthcare company on a mission to eliminate heart attacks by creating a new standard of care for coronary artery disease through FDA-cleared AI-driven solutions that support comprehensive phenotyping usi...

8/ 10Strong

Cyborg Score thesis

Cleerly is positioned to capture significant market share in AI-driven coronary diagnostics with regulatory tailwinds and...

Read the full analyst-debate transcript →
Industry Cardiovascular Devices
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 21, 2026
AI-Verified Research
30+ Page Report

Get the Latest Cleerly, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Cleerly, Inc.

AskCyborg analysts argue the bull and bear cases for Cleerly, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Cleerly, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Cleerly, Inc. Overview

Pro stress-test →

Cleerly is a healthcare company on a mission to eliminate heart attacks by creating a new standard of care for coronary artery disease through FDA-cleared AI-driven solutions that support comprehensive phenotyping using advanced non-invasive CT imaging. The company delivers actionable clinical insights across the entire cardiac care pathway, addressing a critical gap in early disease detection and prevention.

Strategic Profile

Pro stress-test →

Cleerly completed a Series C funding round in November 2024, and recently achieved Medicare coverage and a CPT Category I code for advanced plaque analysis, positioning itself as a market leader in AI-enabled cardiovascular diagnostics. As of May 31, 2026, the company has 354 employees, demonstrating significant scaling momentum in a competitive but undersaturated market.

Competitive Landscape

Pro stress-test →

Top competitors include HeartFlow, Lantheus, and VentriPoint. Cleerly differentiates through comprehensive plaque phenotyping from non-invasive CT, FDA clearance, and integrated clinical-AI approach grounded in large multi-patient datasets. The competitive landscape is consolidating around AI-enabled diagnostics with significant regulatory and reimbursement barriers to entry.

Industry Context

Cleerly, Inc. operates in Cardiovascular Devices.

Key facts

Founded: 2016 · Headquarters: New York, US · Employees: 354 · Revenue: N/A · Market cap: N/A

What the analysts stress-tested

The top findings that survived the multi-agent debate for Cleerly, Inc..

  • FDA-cleared platform with Medicare coverage and CPT Category I code enables rapid commercial scaling and physician adoption in cardiology practices
  • Litigation from HeartFlow (April 2026) over AI technology IP represents near-term risk to commercialization momentum despite strong clinical evidence foundation
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • May 2026MemorialCare systemwide launch bringing AI-powered assessment to Coronary CTA imaging across Long Beach Medical Center and Orange Coast Medical Center
  • April 2026HeartFlow litigation filed over AI cardiology technology claims
  • +2 moreTrack every material event for Cleerly, Inc. as it happens. Explore monitoring →
Get alerted when Cleerly, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

HeartFlowAI-driven coronary CT analysis for ischemia assessment→LantheusCardiovascular imaging and diagnostics→VentriPointCardiac imaging analysis software→

Compare Cleerly, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Cleerly, Inc. operates in Cardiovascular Devices. See how the rest of the sector scores on the Cyborg framework.

Browse Cardiovascular Devices research →
NEW · MCP server

Ask your AI assistant about Cleerly, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Cleerly, Inc. and its top competitor on Cyborg Score”
“What did Cleerly, Inc. do this quarter?”
“Is Cleerly, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Cleerly, Inc. do?+
Cleerly is a healthcare company on a mission to eliminate heart attacks by creating a new standard of care for coronary artery disease through FDA-cleared AI-driven solutions that support comprehensive phenotyping usi...
What is Cleerly, Inc.'s Cyborg Score?+
Cleerly, Inc. has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Cleerly, Inc.'s main competitors?+
Named competitors include HeartFlow, Lantheus, VentriPoint. The full competitive landscape is in the AskCyborg report.
How can I get the full Cleerly, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Cleerly, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Cleerly, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Cardiovascular Devices research

Companies in the same sector and named competitors, ranked by Cyborg Score.

6HeartFlow, Inc.7Lantheus Holdings, Inc.